GONGWIN BIOPHARM HOLDINGS CO., LTD. Gongwin Biopharm Holdings Co., Ltd. Share Price
Equities
6617
KYG409471060
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 181.5 TWD | -0.82% |
|
-1.36% | -1.63% |
| Sales 2022 | 1.14M 35.08K 2.81M | Sales 2023 | 18.92M 581K 46.44M | Capitalization | 20.91B 642M 51.33B |
|---|---|---|---|---|---|
| Net income 2022 | -254M -7.8M -624M | Net income 2023 | -101M -3.1M -248M | EV / Sales 2022 | 30,768 x |
| Net cash position 2022 | 964M 29.59M 2.37B | Net cash position 2023 | 865M 26.55M 2.12B | EV / Sales 2023 | 1,060 x |
| P/E ratio 2022 |
-140
x | P/E ratio 2023 |
-207
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.82% | ||
| 1 week | -1.36% | ||
| Current month | -5.47% | ||
| 1 month | -3.71% | ||
| 3 months | +6.45% | ||
| 6 months | -1.36% | ||
| Current year | -1.63% |
1 week
179.50
188.00
1 month
176.00200.00
Current year
167.00217.00
1 year
167.00319.50
3 years
150.00457.00
5 years
52.70457.00
10 years
47.50457.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mao Yuan Lin
CEO | Chief Executive Officer | - | 30/04/14 |
Wei Nan Hu
DFI | Director of Finance/CFO | - | 31/05/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lieh Lin Chan
BRD | Director/Board Member | - | 03/12/18 |
Chih Tung Yang
BRD | Director/Board Member | - | 27/01/16 |
Lester John Wu
CHM | Chairman | - | 27/01/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 181.5 | -0.82% | 71,542 |
| 25/04/24 | 183 | 0.00% | 39,102 |
| 24/04/24 | 183 | +0.27% | 50,873 |
| 23/04/24 | 182.5 | +0.27% | 60,513 |
| 22/04/24 | 182 | -1.09% | 65,511 |
End-of-day quote Taipei Exchange, April 25, 2024
More quotes
Gongwin Biopharm Holdings Co Ltd is a company engaged in the research and development of anti-cancer medicine, especially focuses on the precise treatment to tumors. The Companyâs headquarter is located in Taiwan and it created a cross-regional platform composed of Taiwan, China Mainland and the United States. The new PTS drug researched and developed by the Company is a new drug product for cancer treatment combined with minimally invasive interventional therapy technology, including PTS100 for the treatment of liver cancer, PTS302 for the treatment of lung cancer, PTS-02 for the treatment of rare diseases, PTS500 for the treatment of malignant pleural effusion and pets medication GWA101 and others.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.63% | 631M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 6617 Stock
